Analysts Issue Forecasts for Edesa Biotech Q3 Earnings

Edesa Biotech, Inc. (NASDAQ:EDSA) – Brookline Capital Markets issued their Q3 2026 earnings per share estimates for shares of Edesa Biotech in a report issued on Monday, June 29th. Brookline Capital Markets analyst K. Raja anticipates that the company will earn ($0.49) per share for the quarter. Brookline Capital Markets has a “Strong-Buy” rating on the stock. The consensus estimate for Edesa Biotech’s current full-year earnings is ($1.57) per share. Brookline Capital Markets also issued estimates for Edesa Biotech’s Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.75) EPS, FY2027 earnings at ($2.11) EPS and FY2028 earnings at ($2.51) EPS.

Edesa Biotech (NASDAQ:EDSA) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.25).

A number of other equities analysts have also recently commented on EDSA. Weiss Ratings reissued a “sell (e+)” rating on shares of Edesa Biotech in a research note on Wednesday, June 24th. Wall Street Zen raised shares of Edesa Biotech from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Edesa Biotech presently has an average rating of “Moderate Buy” and an average price target of $5.00.

Edesa Biotech Trading Down 4.7%

EDSA stock opened at $7.75 on Thursday. The company’s 50 day moving average is $9.51 and its 200 day moving average is $5.38. The stock has a market cap of $68.90 million, a price-to-earnings ratio of -5.78 and a beta of 1.03. Edesa Biotech has a 1-year low of $0.72 and a 1-year high of $20.32.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp purchased a new position in shares of Edesa Biotech during the fourth quarter worth approximately $27,000. Susquehanna International Group LLP purchased a new stake in shares of Edesa Biotech in the 3rd quarter valued at $36,000. Diadema Partners LP purchased a new stake in shares of Edesa Biotech in the 4th quarter valued at $77,000. DRW Securities LLC bought a new position in shares of Edesa Biotech during the 4th quarter valued at $191,000. Finally, Perceptive Advisors LLC bought a new position in shares of Edesa Biotech during the 1st quarter valued at $2,946,000. 5.50% of the stock is currently owned by institutional investors.

About Edesa Biotech

Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.